Related Experiment Videos
Expression and characterization of recombinant human ADAMTS-13
Barbara Plaimauer1, Friedrich Scheiflinger
1Baxter BioScience, Biomedical Research Center, Orth/Donau, Austria.
Seminars in Hematology
|January 17, 2004
Summary
Thrombotic thrombocytopenic purpura (TTP) is linked to von Willebrand factor (VWF) issues and ADAMTS-13 deficiency. Recombinant ADAMTS-13 (rADAMTS-13) offers a potential new therapy and diagnostic tool for TTP.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Thrombotic thrombocytopenic purpura (TTP) involves large von Willebrand factor (VWF) and deficient ADAMTS-13 protease.
- ADAMTS-13 cleaves VWF to prevent microvascular platelet aggregation.
Purpose of the Study:
- To analyze the functional relationship between ADAMTS-13 and TTP pathophysiology.
- To report advances in cell culture expression and functional characterization of human recombinant ADAMTS-13 (rADAMTS-13).
Main Methods:
- Genetic engineering of ADAMTS13 cDNA.
- Cell culture expression of rADAMTS-13.
- In vitro activity studies and functional characterization.
Main Results:
- In vitro expression confirmed ADAMTS-13 deficiency in congenital TTP and inhibition in acquired TTP.
- Characterization of rADAMTS-13 established its functional properties.
- Advances in expression and characterization were achieved.
Conclusions:
- rADAMTS-13 is a valuable tool for studying TTP.
- rADAMTS-13 holds promise for recombinant substitution therapy in TTP treatment.
- Simplified diagnostic assays for TTP may become possible with rADAMTS-13 availability.